Smilax china L. rhizome extract inhibits nuclear factor-κB and induces apoptosis in ovarian cancer cells

Chinese Journal of Integrative Medicine

Volumn 21, Issue 12, 2015, Pages 907-915

  Hu, Li ling ^a,b   Chen, Dong sheng ^b   Wang, Yan yan ^a   Qin, You ^b   Huang, Pu ^b   Yu, Li xiu ^b   Liao, Jing ^b   Hua, Xiao li ^b  

^a CHINA THREE GORGES UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

A2780 cells; apoptosis; chemosensitivity; G2 M arrest; nuclear factor B; Smilax china L. rhizome

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CELLULAR INHIBITOR OF APOPTOSIS 1; CISPLATIN; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 5; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PLANT EXTRACT; PROPIDIUM IODIDE; PROTEIN BAX; PROTEIN BCL XL; PROTEIN KINASE B; SMILAX CHINA RHIZOME EXTRACT D; SMILAX CHINA RHIZOME EXTRACT E; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CELLULAR DISTRIBUTION; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA REPLICATION; DOSE RESPONSE; DOWN REGULATION; DRUG MECHANISM; DRUG RESISTANCE; ENZYME PHOSPHORYLATION; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; M PHASE CELL CYCLE CHECKPOINT; OVARIAN CANCER CELL LINE; PRIORITY JOURNAL; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DRUG EFFECTS; FEMALE; OVARIAN NEOPLASMS; PATHOLOGY; SARSAPARILLA; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; HUMANS; NF-KAPPA B; OVARIAN NEOPLASMS; PLANT EXTRACTS; SMILAX;

EID: 84949111318     PISSN: 16720415     EISSN: 19930402     Source Type: Journal    
DOI: 10.1007/s11655-014-1788-9     Document Type: Article

References (36)

1. Lacassie HJ, Cartagena J, Branes J, Assel M, Echevarria GC. The relationship between neuraxial anesthesia and advanced ovarian cancer-related outcomes in the Chilean population. Anesth Analg 2013;117:653–660.
2. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NFkappaB as the matchmaker. Nat Immunol 2011;12:715–723.
3. Godwin P, Baird AM, Heavey S, Barr MP, O'Byrne KJ, Gately K. Targeting nuclear factor-kappaB to overcome resistance to chemotherapy. Front Oncol 2013;3:120.
4. Chen R, Alvero AB, Silasi DA, Mor G. Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signaling pathway. Am J Reprod Immunol 2007;57:93–107.
5. Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005;5:297–309.
6. Chinese Pharmacopoeia Commission. Pharmacopoeia of the People's Republic of China. Vol. 1 (2005). Beijing: China Medical Science Press;2005:216.
7. Ma Y, Luo Y, Song L, Qin F, Hou L. Pharmaceutical screening of the effective fraction from Smilax for treatment of chronic pelvic inflammatory disease. Nanfang Med Univ (Chin) 2013;33:145–149.
8. Shu XS, Gao ZH, Yang XL. Anti-inflammatory and antinociceptive activities of Smilax china L. aqueous extract. J Ethnopharmacol 2006;103:327–332.
9. Khan I, Nisar M, Ebad F, Nadeem S, Saeed M, Khan H, et al. Anti-inflammatory activities of sieboldogenin from Smilax china Linn.: experimental and computational studies. J Ethnopharmacol 2009;121:175–177.
10. Shao B, Guo H, Cui Y, Ye M, Han J, Guo D. Steroidal saponins from Smilax china and their anti-inflammatory activities. Phytochemistry 2007;68:623–630.
11. Wang T, Yang HS. Experimental studies on anti-tumor effects of Smilax china L. extract of ethylacetate. J Basic Clin Oncol (Chin) 2007;20:129–131.
12. 2/M phase arrest and apoptosis on HeLa cells in a p53-independent manner. Cancer Lett 2008;264:229–240.
13. Wu LS, Wang XJ, Wang H, Yang HW, Jia AQ, Ding Q. Cytotoxic polyphenols against breast tumor cell in Smilax china L. J Ethnopharmacol 2010;130:460–464.
14. Chinese Pharmacopoeia Commission. Pharmacopoeia of the People's Republic of China. Vol. 1 (2010). Beijing: China Medical Science Press;2010:290.
15. Salic A, Mitchison TJ. A chemical method for fast and sensitive detection of DNA synthesis in vivo. Proc Natl Acad Sci USA 2008;105:2415–2420.
16. Man S, Gao W, Zhang Y, Huang L, Liu C. Chemical study and medical application of saponins as anti-cancer agents. Fitoterapia 2010;81:703–714.
17. Raju J, Mehta R. Cancer chemopreventive and therapeutic effects of diosgenin, a food saponin. Nutr Cancer 2009;61:27–35.
18. Brentnall M, Rodriguez-Menocal L, De Guevara RL, Cepero E, Boise LH. Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis. BMC Cell Biol 2013;14:32.
19. Mazumder S, Plesca D, Almasan A. Caspase-3 activation is a critical determinant of genotoxic stress-induced apoptosis. Methods Mol Biol 2008;414:13–21.
20. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995;376:37–43.
21. Masato E, Hideki S, Hideki Y, Katsuya O, Iwamatsu A, Nagatal S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998;391:43–50.
22. Ikejima M, Noguchi S, Yamashita R, Ogura T, Sugimura T, Gill DM, et al. The zinc fingers of human poly (ADP-ribose) polymerase are differentially required for the recognition of DNA breaks and nicks and the consequent enzyme activation. Other structures recognize intact DNA. J Biol Chem 1990;265:21907–21913.
23. Tamer MS, Fariba K. Role of Caspase, PARP, and oxidative stress in male infertility. Oxidative Stress Appl Basic Res Clin Pract 2012:237–254.
24. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998;281:1322–1326.
25. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999;13:1899–1911.
26. Li J, Kim JM, Liston P, Li M, Miyazaki T, Mackenzie AE, et al. Expression of inhibitor of apoptosis proteins (IAPs) in rat granulosa cells during ovarian follicular development and atresia. Endocrinology 1998;139:1321–1328.
27. Deveraux QL, Reed JC. IAP family proteins—suppressors of apoptosis. Genes Dev 1999;13:239–252.
28. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004;6:203–208.
29. Kleinberg L, Dong HP, Holth A, Risberg B, Trope CG, Nesland JM, et al. Cleaved caspase-3 and nuclear factorkappaB p65 are prognostic factors in metastatic serous ovarian carcinoma. Hum Pathol 2009;40:795–806.
30. Shishodia S, Aggarwal BB. Nuclear factor-kappaB activation: a question of life or death. J Biochem Mol Biol 2002;35:28–40.
31. Vandermoere F, El Yazidi-Belkoura I, Adriaenssens E, Lemoine J, Hondermarck H. The antiapoptotic effect of fibroblast growth factor-2 is mediated through nuclear factor-kappaB activation induced via interaction between Akt and I kappa B kinase-beta in breast cancer cells. Oncogene 2005;24:5482–5491.
32. Dan HC, Sun M, Kaneko S, Feldman RI, Nicosia SV, Wang HG, et al. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem 2004;279:5405–5412.
33. Guo RX, Qiao YH, Zhou Y, Li LX, Shi HR, Chen KS. Increased staining for phosphorylated AKT and nuclear factor-κB p65 and their relationship with prognosis in epithelial ovarian cancer. Pathol Int 2008;58:749–756.
34. Alvero AB, Chen R, Fu HH, Montagna M, Schwartz PE, Rutherford T, et al. Molecular phenotyping of human ovarian cancer stem cells unravel the mechanisms for repair and chemo-resistance. Cell cycle 2009;8:158–166.
35. McCarty MF, Block KI. Preadministration of high-dose salicylates, suppressors of NF-kappaB activation, may increase the chemosensitivity of many cancers: an example of proapoptotic signal modulation therapy. Integr Cancer Ther 2006;5:252–268.
36. Li F, Sethi G. Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta 2010;1805:167–180.